Bimzelx Outperforms Skyrizi in Head-to-Head Psoriatic Arthritis Trial, Strengthening the Position of UCB’s Blockbuster Bimzelx | iPharmaCenter

Bimzelx (bimekizumab) showed marked superiority over Skyrizi (risankizumab) in improving symptoms of active psoriatic arthritis, achieving statistically significant results at Week 16 as measured by the ACR50 response.

This marks the first time a licensed biologic therapy has shown clear superiority over an IL-23 inhibitor in psoriatic arthritis. BE BOLD represents the fourth head-to-head study within the Bimzelx clinical program to demonstrate superior outcomes in psoriatic disease, and the first trial conducted specifically in psoriatic arthritis.

UCB has released encouraging topline findings from the BE BOLD study comparing Bimzelx with Skyrizi in adults with active psoriatic arthritis.

Bimzelx, which uniquely blocks both interleukin 17A (IL‑17A) and interleukin 17F (IL‑17F), met its primary objective by achieving statistically significant improvement in ACR50 response rates at Week 16. The therapy was generally well tolerated, and no new safety concerns emerged during the treatment period.

These findings further strengthen the clinical evidence supporting Bimzelx across multiple immune-mediated inflammatory conditions. UCB intends to present the full results of the BE BOLD trial at an upcoming global medical conference.